“Generation of renal specific NAD kinase knockout and transgenic mouse models ” NIH R01

Funding Opportunity Number: PAR-24-203 Deadlines Letter of Intent: September 4, 2024 Submission: October 4, 2024 Objectives The goal of this … Continue reading ““Generation of renal specific NAD kinase knockout and transgenic mouse models ” NIH R01”

NIH: Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01)

Funding Opportunity Number: PAR-24-198 Deadlines: October 4, 2024, November 4, 2024 Description Goal 1 of the National Plan to Address … Continue reading “NIH: Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01)”

“Generation of renal specific NAD kinase knockout and transgenic mouse models ” NIH R01

Funding Opportunity Number: PAR-24-203 Deadlines Letter of Intent: September 4, 2024 Submission: October 4, 2024 Objectives The goal of this … Continue reading ““Generation of renal specific NAD kinase knockout and transgenic mouse models ” NIH R01”

NIH: Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01)

Funding Opportunity Number: PAR-24-198 Deadlines: October 4, 2024, November 4, 2024 Description Goal 1 of the National Plan to Address … Continue reading “NIH: Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01)”

“Generation of renal specific NAD kinase knockout and transgenic mouse models ” NIH R01

Funding Opportunity Number: PAR-24-203 Deadlines Letter of Intent: September 4, 2024 Submission: October 4, 2024 Objectives The goal of this … Continue reading ““Generation of renal specific NAD kinase knockout and transgenic mouse models ” NIH R01”

NIH: Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01)

Funding Opportunity Number: PAR-24-198 Deadlines: October 4, 2024, November 4, 2024 Description Goal 1 of the National Plan to Address … Continue reading “NIH: Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01)”

“Generation of renal specific NAD kinase knockout and transgenic mouse models ” NIH R01

Funding Opportunity Number: PAR-24-203 Deadlines Letter of Intent: September 4, 2024 Submission: October 4, 2024 Objectives The goal of this … Continue reading ““Generation of renal specific NAD kinase knockout and transgenic mouse models ” NIH R01”